Patents Examined by Aurora M Fontainhas
  • Anti-MUC1 antibody-drug conjugate
    Patent number: 11872289
    Abstract: The present invention pertains to novel antibody drug conjugates (ADC) comprising anti-MUC1 antibody. In particular, said ADC showed significant anti-tumor efficacy.
    Type: Grant
    Filed: August 1, 2022
    Date of Patent: January 16, 2024
    Assignee: DAIICHI SANKYO CO., LTD.
    Inventors: Johanna Gellert, Anke Flechner, Doreen Weigelt, Antje Danielczyk, Akiko Nagase
  • Combination therapy of PD-1-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
    Patent number: 11865082
    Abstract: The present invention relates to the combination therapy of specific PD-1-targeted IL-2 variant immunocytokines with specific antibodies which bind human PD-L1.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: January 9, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Douglas Hanahan, Christian Klein, Valeria Nicolini, Pablo Umana, Stephan Wullschleger
  • Engineered anti-IL-2 antibodies
    Patent number: 11851485
    Abstract: Described herein are engineered anti-IL-2 antibodies with modified amino acid sequences. The engineered antibodies would confer modified receptor binding specificity to an IL-2-anti-IL2 antibody complex, inhibiting the binding of IL-2 to CD25. The engineered anti-IL-2 antibodies would facilitate expansion of subsets of effector immune cells and decrease undesirable effects caused by IL-2. Thus, the engineered anti-IL-2 antibodies would be useful in treating disease such as cancer and infection.
    Type: Grant
    Filed: November 16, 2022
    Date of Patent: December 26, 2023
    Assignee: AULOS BIOSCIENCE, INC.
    Inventors: Inbar Amit, Itay Levin, Guy Nimrod, Sharon Fischman, Reut Barak Fuchs, Marek Strajbl, Timothy Wyant, Michael Zhenin, Olga Bluvshtein Yermolaev, Yehezkel Sasson, Noam Grossman, Natalia Levitin, Yanay Ofran
  • Methods and compositions for treating virus-associated inflammation
    Patent number: 11840565
    Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: December 12, 2023
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
  • Anti-transferrin receptor antibody and uses thereof
    Patent number: 11839660
    Abstract: Aspects of the disclosure relate to antibodies that bind to transferrin receptor (e.g., transferrin receptor 1) and complexes comprising the antibody covalently linked to a molecular payload. Methods of using the antibodies are also provided.
    Type: Grant
    Filed: March 10, 2023
    Date of Patent: December 12, 2023
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden, Cody A. Desjardins, Brendan Quinn, John Najim
  • Antibody cocktail against SARS-CoV-2 spike protein
    Patent number: 11834493
    Abstract: Provided herein are antibodies that are useful for treating SARS-CoV-2 infections in a subject. Also provided herein are compositions comprising one or more antibodies, methods of treatment comprising administering one or more antibodies, and kits comprising one or more antibodies.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: December 5, 2023
    Assignee: IMMUNOME, INC.
    Inventors: Matthew K. Robinson, Pavel Nikitin, Michael John Morin, Jillian Dimuzio, Ray Howanski, John P. Dowling
  • Antibodies for binding pathologic forms of calcineurin
    Patent number: 11827718
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, which specifically bind to pathologic forms of calcineurin. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and methods for use of these antibodies.
    Type: Grant
    Filed: May 19, 2021
    Date of Patent: November 28, 2023
    Assignee: University of Kentucky Research Foundation
    Inventors: Susan D. Kraner, Rodney P Guttmann, Christopher M. Norris, Jenna Leigh Gollihue
  • Antibody capable of blocking CD47-SIRPa interaction and application thereof
    Patent number: 11820820
    Abstract: An antibody capable of blocking CD47-SIRPa interaction and an application thereof.
    Type: Grant
    Filed: June 10, 2019
    Date of Patent: November 21, 2023
    Assignee: CHENGDU CONMED BIOSCIENCES CO., LTD.
    Inventors: Bo Chen, Gang Xu, Xuhong Chen, Feng Li, Boyan Zhang, Sijia Huang
  • ILT-binding agents and methods of use thereof
    Patent number: 11802155
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: October 31, 2023
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Dana Yen Mei Duey, Allen James Ebens, Jr., Daniel David Kaplan, Chia-Ying Kao Lam, Kalyani Mondal, Geoffrey William Stone, Yan Wang
  • Immunomodulation and anti-tumor-related nanobody and nucleic acid encoding sequence thereof, and uses of the same
    Patent number: 11795227
    Abstract: The present disclosure provides an immunomodulation and anti-tumor-related nanobody that specifically binds to a human leukocyte antigen-G, a programmed cell death ligand 1, and CD3 ?. The present disclosure also provides the nucleic acid sequence of the immunomodulation and anti-tumor-related nanobody, and use of the immunomodulation and anti-tumor-related nanobody for treating cancer and immune-related disorders.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: October 24, 2023
    Assignee: SHINE-ON BIOMEDICAL CO., LTD.
    Inventors: Der-Yang Cho, Shao-Chih Chiu, Shi-Wei Huang, Chih-Ming Pan, Mei-Chih Chen, Yu-Chuan Lin, Yeh Chen
  • Anti-CD94 antibodies and methods of use thereof
    Patent number: 11795228
    Abstract: The present disclosure relates to antibodies that bind to human CD94, as well as methods, uses, polynucleotides, vectors, host cells, and pharmaceutical compositions related thereto. In some embodiments, the antibodies are human or humanized antibodies that bind to human CD94 and do not block binding between CD94 and HLA-E. In some embodiments, the antibodies cross-react with cynomolgus CD94. In some embodiments, the antibodies do not promote internalization of surface-expressed CD94 to the extent of existing antibodies. In some embodiments, the antibodies promote ADCC targeting cells that express human CD94, e.g., on the cell surface.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: October 24, 2023
    Assignee: Dren Bio, Inc.
    Inventors: Nenad Tomasevic, Ruo Shi Shi
  • Anti-CD200R1 antibodies and methods of use thereof
    Patent number: 11787861
    Abstract: The present disclosure provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human CD200R1 receptor protein (hu-CD200R1) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by hu-CD200R1. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CD200 binding to CD200R1.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 17, 2023
    Assignee: 23andMe, Inc.
    Inventors: Yu Chen, Jilean Beth Fenaux, Germaine Fuh-Kelly, Yao-Ming Huang, Wei-Jen Chung, Erik Edward Karrer, Cecilia Lay, Steven J. Pitts, Louise Scharf
  • Identification and analysis of protein biomarkers
    Patent number: 11774457
    Abstract: Protein biomarkers may be used to rapidly and accurately diagnose stroke. Biomarkers may be utilized in a rapid and inexpensive test that could be used at the bedside or ambulatory setting to definitively indicate the presence or absence of stroke and its severity. Such a test would quickly stratify patients in need of immediate stroke treatment from those who are not having a stroke. The test may aid emergency personnel in the decision for the most appropriate treatment plan and treatment location, thereby minimizing morbidity and mortality of stroke patients.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: October 3, 2023
    Assignee: Wright State University
    Inventors: James Edwin Olson, April Daubenspeck, David Cool, Bryan Ludwig
  • Personalized immunotherapy against several neuronal and brain tumors
    Patent number: 11759507
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: September 19, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
  • Theranostics for protein misfolding diseases
    Patent number: 11759520
    Abstract: Novel agents and theranostics for use as controllable and selective photosensitizers for the diagnosis, treatment and/or tracking of amyloid protein aggregates and amyloid diseases.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: September 19, 2023
    Assignee: UNM Rainforest Innovations
    Inventors: Eva Y. Chi, David G. Whitten, Patrick Donabedian, Florencia A. Monge, Matthew Creyer, Adeline Fanni, Jonathan Hulse
  • ILT3-binding agents and methods of use thereof
    Patent number: 11760802
    Abstract: The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: September 19, 2023
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Suzanne Christine Crawley, Jer-Yuan Hsu, Daniel David Kaplan, Betty Chan Li, Vicky Yi-Bing Lin, Seth Malmersjö, Kevin James Paavola, Julie Michelle Roda, Yan Wang
  • Bispecific binding agents binding to CLDN18.2 and CD3
    Patent number: 11739145
    Abstract: The present invention provides binding agents comprising at least two binding domains, wherein a first binding domain has specificity for CLDN18.2 and a second binding domain has specificity for CD3, and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.
    Type: Grant
    Filed: December 6, 2022
    Date of Patent: August 29, 2023
    Inventors: Matthew Bernett, Alex Nisthal, Gregory Moore
  • Modified anti-PD-L1 antibody and methods and uses for treating a neurodegenerative disease
    Patent number: 11732046
    Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: August 22, 2023
    Assignees: ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
    Inventors: Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
  • Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
    Patent number: 11718652
    Abstract: The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: August 8, 2023
    Assignees: Salubris Biotherapeutics, Inc.
    Inventors: John Li, Shengwei Li, Dixiang Luo, Yiran Wu, Ming Zhou, Yang Wang, Xiaolei Zhuang, Liang Hua, Pengyi Luo
  • Psilocybin compositions
    Patent number: 11701348
    Abstract: Methods and compositions are disclosed for enhancing neurogenesis, resolving neuropathy and improving neurological health and functioning using fungal extracts and their active ingredients, including species of mushrooms and mycelia containing psilocybin and psilocin, combined with erinacines and hericenones or fungal extracts containing those active ingredients, with the addition of nicotinic acid. The compositions may optionally be combined with nervine plants.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: July 18, 2023
    Assignee: TURTLE BEAR HOLDINGS, LLC
    Inventor: Paul Edward Stamets